Simulations Plus, Inc. reported a revenue increase of 13% for the fiscal year ending August 31, 2025, reaching $79.2 million compared to $70.0 million in the previous year. This growth was primarily driven by the full-year contribution of $11.7 million from the Pro-ficiency acquisition, which was completed in June 2024. However, the company also faced significant challenges, including a substantial impairment charge of $77.2 million, which negatively impacted its profitability. The net loss for the year was $64.7 million, a stark contrast to the net income of $10.0 million reported in the prior fiscal year.
The company's cost of revenue rose by 23% to $33.0 million, largely due to increased software-related costs associated with the Pro-ficiency acquisition and higher service-related expenses. Gross profit increased by 7% to $46.2 million, but the gross margin declined from 62% to 58%, reflecting the underperformance of Pro-ficiency revenues. Operating expenses surged to $117.0 million, primarily due to the impairment charges and increased spending in research and development, sales and marketing, and general administrative costs.
In terms of operational developments, Simulations Plus underwent a significant reorganization at the beginning of the fourth quarter of fiscal 2025, transitioning to a function-based structure aimed at enhancing operational efficiency. The company also reported a workforce reduction of approximately 10% as part of its 2025 Restructuring Plan, which is expected to yield annualized savings of about $4.3 million. As of August 31, 2025, the company employed 213 individuals, a decrease from the previous year.
Geographically, the Americas accounted for 73% of total revenue, while the EMEA and Asia Pacific regions contributed 18% and 9%, respectively. The company continues to focus on expanding its market presence and enhancing its product offerings, particularly in the biopharma sector, where it provides advanced software and consulting services for drug development. Looking ahead, Simulations Plus aims to leverage its recent acquisitions and restructuring efforts to drive growth and improve financial performance, although it acknowledges the ongoing challenges posed by market conditions and competition in the industry.
About Simulations Plus, Inc.
Simulations Plus, Inc. provides software and consulting services for drug discovery, development, and regulatory approval. Its core offerings include modeling and simulation tools like GastroPlus and ADMET Predictor, supporting pharmaceutical, biotech, and academic clients worldwide. The company enhances R&D efficiency, reduces costs, and accelerates time-to-market through innovative science-based solutions across the drug development continuum. It operates with a focus on scientific expertise, proprietary technology, and global customer relationships.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.